Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAP-Exd + ATR inhibitor
- Development stage
- Preclinical
- Lead developer
- Avacta
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
FAP-Exd + ATR inhibitor is an experimental combination therapy designed to target the tumor microenvironment and enhance DNA damage-induced cell death. FAP-Exd is a recombinant fusion protein consisting of a single-chain variable fragment (scFv) targeting Fibroblast Activation Protein (FAP) and the GLP-1 receptor agonist Exendin-4. It specifically targets FAP-expressing cancer-associated fibroblasts (CAFs), which are prevalent in the stroma of many solid tumors. By activating GLP-1R on these fibroblasts, FAP-Exd modulates the stroma to improve immune infiltration and drug sensitivity. The ATR inhibitor component (such as ceralasertib) inhibits the Ataxia Telangiectasia and Rad3-related (ATR) kinase, a key regulator of the DNA damage response. This combination aims to synergistically disrupt the protective stromal barrier and exploit the replication stress of tumor cells, potentially providing a new strategy for treating stroma-rich cancers like pancreatic ductal adenocarcinoma.
- Other names
- FAP-targeted Exendin-4 + ATR inhibitor
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on FAP-Exd + ATR inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAP-Exd + ATR inhibitor.